1.Floreani, A, et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004; 22: 608–611.
2.European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 12: 561–565.
3.FitzSimons, D, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005; 23: 4158–4166.
4.Gabbuti, A, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007; 25: 3129–3132.
5.Hammitt, LL, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: A follow-up study at 15 years. Vaccine 2007; 25: 6958–6964.
6.Lin, YC, et al. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. Journal of Infectious Diseases 2003; 187: 134–138.
7.Watson, B, et al. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001; 19: 3164–3168.
8.Zanetti, A, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379–1384.
9.Shaw, FE, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7: 425–430.
10.Bryan, JP, et al. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clinical Infectious Diseases 1992; 14: 697–707.
11.Weber, DJ, et al. Obesity as a predictor of poor antibody response to hepatitis B plasma. Journal of the American Medical Association 1985; 254: 3187–3189.
12.Zuckerman, JN. Nonresponse to hepatitis B vaccines and the kinetics of Anti-HBs production. Journal of Medical Virology 1996; 50: 283–288.
13.Dentinger, C, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatric Infectious Disease Journal 2005; 24: 786–792.
14.Koff, RS. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 2002; 20: 3695–3701.
15.Wang, R, et al. Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination. World Journal of Gastroenterology 2004; 10: 260–263.
16.Bauer, T, Jilg, W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572–577.
17.Banatvala, JE, Van Damme, P. Hepatitis B vaccine – do we need boosters? Journal of Viral Hepatitis 2003; 10: 1–6.
18.Ständige Impfkommission am Robert Koch-Institut. Recommendations of the German Standing Vaccination Committee (STIKO) at the Robert Koch Institute (as of July 2007) [in German]. Epidemiologisches Bulletin 2007; 30: 267–286.
19.Poethko-Müller, C, Kuhnert, R, Schlaud, M. Vaccination coverage and predictors for vaccination level. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50: 851–862.
20.Kalies, H, et al. Immunisation status of children in Germany: temporal trends and regional differences. European Journal of Pediatrics 2006; 165: 30–36.
23.Kilpi, T, et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11–12 months of age. Human Vaccines 2009; 5: 18–25.
24.Mallet, E, et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatric Infectious Disease Journal 2000; 19: 1119–1127.
25.Mallet, E, et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 2004; 22: 1343–1357.
26.Tichmann, I, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccines and evaluation of booster vaccination. Human Vaccines 2006; 2: 249–254.
27.Tichmann, I, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005; 23: 3272–3279.
28.Kurth, B-M, et al. The challenge of comprehensively mapping children's health in a nation-wide health survey: design of the German KiGGS Study. BMC Public Health 2008; 8: 196.
29.Hölling, H, et al. The German Health Interview and Examination Survey for Children and Adolescents (KiGGS): study management and conduct of fieldwork [in German]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50: 557–566.
30.Thierfelder, W, et al. Biochemical measures in the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50: 757–770.
31.Jilg, W, Schmidt, M, Deinhardt, F. Persistence of specific antibodies after hepatitis B vaccination. Journal of Hepatology 1988; 6: 201–207.
32.van der Sande, MA, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. Journal of Infectious Diseases 2006; 193: 1528–1535.
33.McMahon, BJ, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Annals of Internal Medicine 2005; 142: 333–341.
34.Faustini, A, et al. Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy. Vaccine 2001; 19: 2812–2818.
35.Giambi, C, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infectious Diseases 2008; 8: 100.
36.Heininger, U, et al. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007; 25: 1055–1063.
37.Kesler, K, et al. Immune responses of prematurely born infants to hepatitis B vaccination: results through three years of age. Paediatric Infectious Disease Journal 1998; 17: 116–119.
38.Losonsky, GA, et al. Hepatitis B vaccination of premature infants: A reassessment of current recommendations for delayed immunization. Pediatrics 1999; 103: e14.
39.Lau, YL, et al. Response of preterm infants to hepatitis B vaccine. Journal of Pediatrics 1992; 121: 962–965.
40.Olivier, C, et al. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine 2008; 26: 3142–3152.
41.Tichmann-Schumann, I, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus three-component acellular pertussis-hepatitis B-inactivated polio virus Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal 2005; 24: 70–77.
42.Da Villa, G, et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007; 25: 3133–3136.
43.Bialek, SR, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatric Infectious Disease Journal 2008; 27: 881–885.
44.Whittle, H, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. British Medical Journal 2002; 14: 569–573.
45.Samandari, T, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120: e373–e381.
46.Walter, J, et al. Hepatitis B and C risk factors in Germany – results of the national surveillance [in German]. Gesundheitswesen 2005; 67: 441–447.
47.Swissmedic. Notification to health experts, 20 September 2005: Swissmedic suspends the license of the Hexavac vaccine [in German]. Swissmedic Journal 2005; 9: 678–679.